Cipla Limited

NSE:CIPLA.NS

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🔬 Clinical Trials

💊 Drugstores & Retail Pharmacies

Location

India

Market Cap

USD 14.16 B

Share Price

USD 17.50

Avg Daily Volume

1,651,707

Change (1 day)

0.80%

Change (1 year)

-2.78%

Change (YTD)

-2.02%

Cipla Limited Share Price on June 24, 2025: USD 17.50

Cipla Limited Share Price is USD 17.50 on June 24, 2025, a -2.78% change year over year. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance.

Cipla Limited 52-week low Share Price is USD 20.01 on June 24, 2025, which is 14.36% above the current Share Price.
Cipla Limited 52-week low Share Price is USD 16.07 on June 24, 2025, which is -8.18% below the current Share Price.
Cipla Limited average Share Price for the last 52 weeks is USD 17.81.

Daily

From:

To:

Zoom:

Key data

Date	Share Price	Share Price	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)

NSE: CIPLA.NS

Cipla Limited

CEO	Mr. Umang Vohra B.E., M.B.A.
IPO Date	Jan. 1, 1996
Location	India
Headquarters	Cipla House
Employees	27,764
Sector	🏥 Health Care
Industries Pharmaceuticals 🔬 Clinical Trials 💊 Drugstores & Retail Pharmacies

Description

Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. It also provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Cipla Limited has a licensing agreement with Merck & Co., Inc. for the manufacturing and distribution of Molnupiravir, an investigational oral antiviral drug; a license agreement with Eli Lilly and Company for the manufacture and commercialization of the drug baricitinib for Covid-19 indication; and collaborations with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for the clinical trial of the investigational oral anti-viral drug Molnupiravir. The company was incorporated in 1935 and is headquartered in Mumbai, India.